Alfasigma has signed an exclusive licensing agreement with PhaseBio Pharmaceuticals for commercialization of bentracimab
Italian drugmaker Alfasigma has signed an exclusive licensing agreement with USA-based cardiopulmonary diseases centered organization PhaseBio Pharmaceuticals (Nasdaq: PHAS) for
Read more